February 10, 2025

Guerbet’s Lipiojoint Liquid Embolic Granted FDA Breakthrough Device Status

February 10, 2025—Guerbet announced that its Lipiojoint transient liquid embolic agent received Breakthrough Device status from the United States FDA.

According to the company, the Lipiojoint embolic agent is being developed for genicular artery embolization. Lipiojoint is designed to alleviate pain and the related burden of reduced mobility in patients with knee osteoarthritis.

Marc Sapoval, MD, et al recently published clinical data from the Lipiojoint-1 study (NCT04733092), which demonstrated promising patient outcomes in pain reduction and knee function. Dr. Sapoval is Head of the Vascular and Oncological Interventional Radiology Department at Hôpital Georges Pompidou, in Paris, France.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

February 10, 2025

Guerbet’s Lipiojoint Liquid Embolic Granted FDA Breakthrough Device Status

Current Issue

Keep In Touch